loading page

Eosinophilia Associated With The Use Of Carfilzomib In A Patient With Multiple Myeloma: A Case Report and review of literature
  • Viera Sandecka,
  • Ludek Pour
Viera Sandecka
University Hospital Brno Internal hematology and oncology clinic

Corresponding Author:[email protected]

Author Profile
Ludek Pour
Fakultni Nemocnice Brno
Author Profile


Multiple myeloma had been an incurable hematological malignancy, recent advances in novel anti-neoplastic agents, including carfilzomib (CFZ), have improved the prognosis. CFZ has been reported to have cardiotoxic effects. Notably, the incidence of peripheral blood eosinophilia was not described. This is the first report of eosinophilia developing after CFZ.
11 May 2020Submitted to Clinical Case Reports
23 Jul 2020Assigned to Editor
23 Jul 2020Submission Checks Completed
12 Aug 2020Reviewer(s) Assigned
25 Apr 2021Review(s) Completed, Editorial Evaluation Pending
03 May 2021Editorial Decision: Revise Minor